Elevation Oncolo SEC Filings

Encompass Capital Advisors LLC and its managing member Todd J. Kantor have filed a Schedule 13G reporting a passive ownership of 5,206,191 Sable Offshore Corp. common shares, representing 5.24 % of the outstanding class as of 17 Jul 2025 (CUSIP 78574H104).

The filing shows shared voting and dispositive power over the entire position and no sole authority. Encompass is classified as an investment adviser (IA), while Kantor is listed as both a control person (HC) and individual (IN). The certification affirms the stake was not acquired to change or influence control of the issuer.

Crossing the 5 % threshold triggers this disclosure under Rule 13d-1; however, no additional financial data, governance proposals, or transactional intentions are provided.

GT Biopharma (GTBP) filed an 8-K summarizing the results of its 24 Jul 2025 annual meeting. 58.9% of the 3.15 M outstanding shares were represented.

• Board elections: All four director nominees—Michael Breen, Charles Casamento, Hilary Kramer and David C. Mun-Gavin—were re-elected; support ranged 98.8-99.0% of votes cast, with 658.5 k broker non-votes.
• Auditor: Weinberg & Company, P.A. was ratified for FY-25 (96.8% FOR).
• Say-on-pay: Advisory approval of executive compensation passed with 97.3% FOR.
• Nasdaq Rule 5635 share issuance: Shareholders approved the potential issuance of ≥19.99% of common stock related to May 2025 financing agreements (97.3% FOR), enabling conversion of Series L 10% Preferred and exercise of associated warrants.
• Incentive plan: Amendment adding 583,334 shares to the 2022 Omnibus Incentive Plan passed (96.0% FOR).

No earnings data were provided. All proposals passed comfortably, clearing governance and capital-raising hurdles but creating potential dilution if convertible securities and warrants are exercised.

Global Mofy AI Limited (GMM) reports the full resolution of its April-2025 PIPE warrants. Purchasers first surrendered 25 % (≈2.55 m) of the 10.20 m warrants, leaving 7.65 m outstanding. Between 8-21 July 2025, those remaining warrants were fully exercised via the 0.8× cashless alternative, converting into 6,117,316 Class A ordinary shares. Because the exercise was cashless, the company received no incremental cash.

Following the issuance, share count stands at 25,495,761 Class A and 3,723,975 Class B shares. The new shares—about 24 % of the current Class A total—are registered under the effective Form F-1 (333-287230). This Form 6-K is also incorporated by reference into the company’s Form F-3 shelf (333-284554).

The update removes a sizeable derivative overhang, simplifying the capital structure, but simultaneously dilutes existing holders without providing fresh capital. No financial results, cash-flow data, or guidance were disclosed.

Shimmick Corp. (SHIM) – Form 144 filing discloses that insider Mitchell B. Goldsteen plans to sell up to 3,900 common shares through TD Securities on or about 24 Jul 2025. At the most recent market price used in the filing, the sale would raise roughly $8.1 k. The proposed shares represent less than 0.01 % of the company’s 34.36 m shares outstanding.

The notice also lists an extensive series of prior open-market sales by Goldsteen during the past three months. Adding the individual transactions shown, the insider has already disposed of ≈252 k shares, generating cumulative gross proceeds of several hundred thousand dollars. The new 3,900-share lot suggests continued selling momentum.

No financial performance data, corporate events or explanatory remarks accompany the filing; Form 144 only signals a potential disposition. Investors typically view persistent insider selling—particularly at this scale—as a bearish sentiment indicator, although the absolute percentages remain small relative to total shares outstanding.

MillerKnoll, Inc. (MLKN) – Form 4 filing for Chief Strategy & Technology Officer Megan C. Lyon, dated 07/24/2025.

On 07/22/2025 Lyon converted 35,376 restricted stock units (RSUs) into common shares (Transaction Code “M”) at a stated price of $0.00, increasing her direct common-stock holdings to 74,371.33 shares immediately after the conversions. To satisfy withholding obligations, she disposed of 10,499.198 shares at $19.50 per share (Transaction Code “F”), leaving 63,872.13 shares held directly.

Following the transactions, Lyon retains 53,931 unvested RSUs (down from 59,176). Of these, 30,131 RSUs represent her fiscal 2024 annual incentive bonus (cliff-vest 07/22/2025) and 5,245 RSUs follow a 33%/33%/34% annual vest schedule through 2027.

Net result: Lyon’s equity exposure increased by ~24.9 k shares; all sales were automatic tax-withholding sales rather than open-market disposals. No other insider or company-level financial data is included.

Coca-Cola Consolidated (COKE) Q2-25 10-Q highlights

• Net sales rose 3.3% YoY to $1.86 bn; first-half sales up 1.4% to $3.44 bn.
• Gross profit +3.6% to $742 m; gross margin steady at 40.0%.
• Operating income +5.0% to $272 m; operating margin 14.7% (+30 bp).
• Net income increased 8.5% to $187 m; diluted EPS $2.15 (+16%). First-half EPS $3.34 (-8%).
• Interest expense swung to a $6 m cost from a $2 m benefit YoY, reflecting higher average debt after 2024 bond issuance.
• Mark-to-market expense on acquisition-related contingent consideration fell to $12 m vs $28 m, easing below-the-line pressure.
• 1H-25 operating cash flow slipped 7% to $406 m; capex $157 m kept free cash flow modest.
• Cash & equivalents climbed to $1.22 bn; total debt unchanged at $1.79 bn, leaving net debt of $0.57 bn.
• Equity strengthened to $1.63 bn as retained earnings rose and buybacks ($35 m) reduced share count under the $1 bn program.
• Dividend lifted to $0.25 per share post 10-for-1 split effective 27-May-25.

Takeaway: Stable volume-driven revenue growth and cost discipline are expanding margins, but higher financing costs and softer first-half earnings temper the story. Robust liquidity and active capital returns support shareholder value.

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller’s name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Elevation Oncology (ELEV) filed five Post-Effective Amendments to prior Form S-8 registration statements to deregister all unsold shares tied to its 2019 Stock Incentive Plan, 2021 Equity Incentive Plan and 2021 ESPP. The move follows the 23 Jul 2025 closing of the merger with Concentra Biosciences, after which Elevation became a wholly owned subsidiary and its public offerings ceased.

Under the merger each common share was converted into $0.36 in cash plus one non-transferable contingent value right (CVR). Approximately 14.3 million shares—about 9.7 m under the 2021 Plan, 1.7 m under the ESPP and 2.4 m under the 2019 Plan—are being withdrawn from registration. The filing removes any future equity issuance from these plans and formally ends the company’s S-8 reporting obligations.

Elevation Oncology (ELEV) filed five Post-Effective Amendments to prior Form S-8 registration statements to deregister all unsold shares tied to its 2019 Stock Incentive Plan, 2021 Equity Incentive Plan and 2021 ESPP. The move follows the 23 Jul 2025 closing of the merger with Concentra Biosciences, after which Elevation became a wholly owned subsidiary and its public offerings ceased.

Under the merger each common share was converted into $0.36 in cash plus one non-transferable contingent value right (CVR). Approximately 14.3 million shares—about 9.7 m under the 2021 Plan, 1.7 m under the ESPP and 2.4 m under the 2019 Plan—are being withdrawn from registration. The filing removes any future equity issuance from these plans and formally ends the company’s S-8 reporting obligations.